High Growth Tech Stocks In South Korea To Watch

The South Korea stock market has ticked lower in back-to-back sessions, slipping almost 10 points or 0.4 percent along the way. The KOSPI now rests just beneath the 2,700-point plateau and it may take further damage again on Tuesday as global forecasts for Asian markets are mixed to lower, with profit-taking expected following recent optimism over interest rates. In such a volatile environment, identifying high-growth tech stocks that can weather market fluctuations and capitalize on emerging opportunities is crucial for investors looking to navigate the current economic landscape effectively.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	33.61%	52.05%	★★★★★★
IMLtd	20.76%	106.30%	★★★★★★
Bioneer	22.49%	89.69%	★★★★★★
FLITTO	32.07%	100.38%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
NEXON Games	31.70%	66.31%	★★★★★★
Devsisters	26.11%	65.92%	★★★★★★
AmosenseLtd	24.29%	55.45%	★★★★★★
Park Systems	22.50%	37.52%	★★★★★★
UTI	103.56%	122.67%	★★★★★★

Click here to see the full list of 51 stocks from our KRX High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩16.60 billion.

Operations: ALTEOGEN Inc. generates revenue primarily from its biotechnology segment, amounting to ₩90.79 million. The company's focus areas include long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

ALTEOGEN’s recent approval of Tergase® by the Ministry of Food and Drug Safety (MFDS) in Korea highlights its innovative Hybrozyme™ Technology, which ensures over 99% purity and lower immunogenicity for recombinant hyaluronidase. This product's application spans from dermal filler removal to orthopedics pain management, positioning it uniquely against traditional animal-derived alternatives. With R&D expenses accounting for ₩36 billion ($27 million) last year, ALTEOGEN is poised to leverage its technological advancements into broader market applications. Revenue is forecasted to grow at an impressive 64.2% annually, significantly outpacing the Korean market's average growth rate of 10.7%.

• Get an in-depth perspective on ALTEOGEN's performance by reading our health report here.

• Assess ALTEOGEN's past performance with our detailed historical performance reports.

Celltrion (KOSE:A068270)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Celltrion, Inc., along with its subsidiaries, specializes in developing and producing protein-based drugs for oncology treatment in South Korea, with a market cap of ₩42.30 trillion.

Operations: Celltrion, Inc. generates revenue primarily from its Bio Medical Supply segment (₩3.54 trillion) and Chemical Drugs segment (₩507.02 billion). The company focuses on developing and producing protein-based drugs for oncology treatment in South Korea.

Celltrion's recent European Commission approval for SteQeyma® (CT-P43) marks a significant milestone in its biosimilar portfolio, targeting chronic inflammatory diseases. The company has also repurchased 410,734 shares for ₩75.89 billion ($57 million) this year to enhance shareholder value. With R&D expenses at ₩120 billion ($90 million), Celltrion's focus on innovation is evident, especially as revenue is forecasted to grow 25.7% annually and earnings by 59.8%, outpacing the Korean market’s average growth of 10.7%.

• Navigate through the intricacies of Celltrion with our comprehensive health report here.

• Gain insights into Celltrion's past trends and performance with our Past report.

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. engages in music production, publishing, and artist development and management businesses with a market cap of ₩7.38 billion.

Operations: HYBE generates revenue primarily from its Label segment (₩1.28 billion) and Solution segment (₩1.24 billion), with additional contributions from its Platform segment (₩361.12 million). The company's diverse revenue streams highlight its multifaceted approach to the music industry, encompassing production, publishing, and artist management.

HYBE’s earnings growth of 21.6% last year outpaced the entertainment industry’s 12.6%, despite a one-off loss of ₩189.4 billion impacting its recent financial results. The company forecasts annual profit growth at 42.5%, significantly above the KR market's 28.8%. With revenue expected to grow at 14% per year, HYBE is investing heavily in innovation, evidenced by substantial R&D expenses contributing to its dynamic business segments and future prospects in high-growth tech markets within South Korea.

• Unlock comprehensive insights into our analysis of HYBE stock in this health report.

• Gain insights into HYBE's historical performance by reviewing our past performance report.

Turning Ideas Into Actions

• Reveal the 51 hidden gems among our KRX High Growth Tech and AI Stocks screener with a single click here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com